Skip to main content
SpringerLink
Log in

Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Elevated plasma B-type natriuretic peptide (BNP) level is a hallmark of altered left ventricular (LV) structure and function. Measurement of circulating BNP has proved to be a sensitive and specific diagnostic test for congestive heart failure (CHF) and coronary syndrome in adults. Further, BNP levels constitute a strong predictive marker for future cardiovascular (CV) events. In high CV risk populations, such as adults with hypertension or chronic kidney disease (CKD), increased BNP predicts CV morbidity and mortality in symptomatic or asymptomatic patients. However, caution is needed in interpreting plasma BNP levels, as they increase with both age and decreased renal function. Despite increasing evidence of the value of BNP in the medical literature in adults, data in children are limited to those with congenital heart disease. It is appropriate to analyze the potential application of this tool in children with CKD, a well-known factor for CV disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mitsnefes MM (2002) Pediatric end-stage renal disease: heart as target. J Pediatr 141:162–164

    Article  PubMed  Google Scholar 

  2. The USRDS 2004 Annual Report (2004) Pediatric end-stage renal disease.http://www.usrds.org

  3. Gruppen MP, Groothoff JW, Prins M, et al (2003) Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int 63:1058–1065

    Article  PubMed  Google Scholar 

  4. Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197

    Article  PubMed  Google Scholar 

  5. Levin RE, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321–328

    Article  PubMed  Google Scholar 

  6. Kyuma M, Nkata T, Hshimoto A, Nagao K, Sasao H, Takahshi T, Tsuchihashi K, Shimamoto K (2004) Incremental prognosis implications of brain natriuretic peptide, cardiac sympathetic nerve innervations and noncardiac disorders in patients with heart failure. J Nucl Med 45:155–163

    PubMed  Google Scholar 

  7. Yamamoto K, Burnet JC, Jougasaki M, Nishimura RA, Bailey KR, Saito K, Nakao K, Redfield MM (1996) Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28:988–994

    PubMed  Google Scholar 

  8. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H (1996) Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28:22–30

    PubMed  Google Scholar 

  9. Nishikimi T, Futoo Y, Tamano K, Takahashi M, Suzuki T, Minami J, et al (2001) Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J kidney Dis 37:1201–1208

    PubMed  Google Scholar 

  10. Ishizaka Y, Yamamoto Y, Fukunaga T, et al (1994) Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis 24:46–72

    Google Scholar 

  11. Westerlind A, Wahlander H, Lindstedt G, Lumberg PA, Holmgren D (2004) Clinical signs of heart failure are associated with increased levels of natriuretic peptides types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 93:340–345

    Article  PubMed  Google Scholar 

  12. Claudius I, Lan YT, Chang RK, Wetzel GT, Alejos J (2003) Usefulness of B-type natriuretic peptide as noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol 92:1368–1370

    Article  PubMed  Google Scholar 

  13. Ruskoaho H (2003) Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 24:341–356

    Article  PubMed  Google Scholar 

  14. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2003) Clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41 [Suppl]:S1–S91

    Google Scholar 

  15. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105

    Article  PubMed  Google Scholar 

  16. Dhingra H, Roongsritong C, Kurtzman NA (2002) Brain natriuretic peptide: role in cardiovascular and volume homeostasis. Semin Nephrol 22:423–437

    Article  PubMed  Google Scholar 

  17. Cameron VA, Ellmers LJ (2003) Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology 144:2191–2194

    Article  PubMed  Google Scholar 

  18. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362:316–322

    Article  PubMed  Google Scholar 

  19. Jortani SA, Prabbu SD, Valdes R (2004) Strategies for developing biomarkers of heart failure. Clin Chem 50:265–278

    Article  PubMed  Google Scholar 

  20. Clerico A, Emdin M (2004) Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50:33–50

    Article  PubMed  Google Scholar 

  21. Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Temma S, et al (1995) Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 133:207–209

    PubMed  Google Scholar 

  22. Kunii Y, Kamada M, Ohtsuki S, Araki T, et al (2003) Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 57:191–197

    PubMed  Google Scholar 

  23. Koch A, Singer H (2003) Normal values of B type natriuretic peptide in infants, children and adolescents. Heart 89:875–878

    Article  PubMed  Google Scholar 

  24. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982

    Article  PubMed  Google Scholar 

  25. Wang TJ, Larson MG, Levy D, et at (2003) Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108:13–16

    Article  PubMed  Google Scholar 

  26. Wang TJ, Larson MG, Levy D, Benjamin EJ, Corey D, Leip EP, et al (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109:595–600

    Google Scholar 

  27. McCullough PA, Sandberg KR (2003) Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 4[Suppl 4]: S13–S19

  28. Nakatami T, Nagamuna T, Masuda C, Uchida J, Sugimura T, Sugimura K (2002) Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis. Int J Mol Med 10:457–461

    PubMed  Google Scholar 

  29. Naganuma T, Sugimura K, Wada S, et al (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22:437–444

    Article  PubMed  Google Scholar 

  30. Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara F, et al (2004) Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 44:420

    PubMed  Google Scholar 

  31. Yano Y, Katsuki A, Gabazza EC, Ito K, Fujii M, Furuta M, et al (1999) Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 84:2353–2356

    Article  PubMed  Google Scholar 

  32. Biosite (2002) TriageBNP package insert. Biosite, San Diego

  33. McCullough PA, Duc P, Omland T, et al (2003) B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis 41:571–579

    Article  PubMed  Google Scholar 

  34. Ishii J, Cui W, Kitagawa F, et al (2003) Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 49:2020–2026

    Article  PubMed  Google Scholar 

  35. Bruins S, Fokkema MR. Romer JWP, et al (2004) High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50:2052–2058

    Article  PubMed  Google Scholar 

  36. Kurotobi S, Kawakami N, Shimizu K, et al (2005) Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki Disease. Pediatr Cardiol, Han 13, Epub ahead of print

  37. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 45:249–254

  38. Lan YT, Chang RKR, Alejos JC, Burch C, Wetzel GT (2004) B-type natriuretic peptide in children after cardiac transplantation. J Heart Lung Transplant 23:558–563

    Article  PubMed  Google Scholar 

  39. Kario K, Nishikimi T, Toshikaara F, Takishita S, Yamakoa R, Matsuo T, Matuso H, Mithuhashi T, Shimada K, Kangawa K (1998) Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24 h blood pressure. J Hypertens 16:1253–1259

    Article  PubMed  Google Scholar 

  40. Hoshide S, Kario K, Hoshide Y, Umeda Y, Hashimoto T, Kunii O, Ojima T, Shimada K (2003) Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 16:434–438

    Article  PubMed  Google Scholar 

  41. Kato J, Kitamura K, Uemura T, et al (2002) Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 25:887–892

    Article  PubMed  Google Scholar 

  42. Freitag MH, Laron MG, Levy D, Benjamin EJ, et al (2003) Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension 41:978–983

    Article  PubMed  Google Scholar 

  43. Mussalo H, Vanninen E, Ikäheimo R, Hartikainen J (2003) NT-proANP and BNP in renovascular and in severe and mild essential hypertension. Kidney Blood Press Res 26:34–41

    Google Scholar 

  44. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K (2002) Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 25:669–676

    Article  PubMed  Google Scholar 

  45. Grandi AM, Laurita E, Selva E, Piantanida E, Imperiale D, Giovanella L, et al (2004) Natriuretic peptides as markers of preclinical cardiac disease in obesity. Eur J Clin Invest 34:342–348

    Article  PubMed  Google Scholar 

  46. Lee SW, Song JH, Kim GA, Lim HJ, Kim MJ (2003) Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis 41:1257–1266

    Article  PubMed  Google Scholar 

  47. Cataliotti A, Malatino LS, Jougasaki M, et al (2001) Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 76:1111–1119

    PubMed  Google Scholar 

  48. Goto T, Takase H, Toriyama T, et al (2002) Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 92:610–615

    Article  PubMed  Google Scholar 

  49. Naganuma T, Sugimura K, Wada S, et al (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 22:437–444

    Article  PubMed  Google Scholar 

  50. McCullough PA, Joseph K, Mathur VS (2004) Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med 5:16–25

    PubMed  Google Scholar 

  51. Groothoff J, Gruppen M, Offringa M, De Groot E, Stok W, Bos W, Davin J, Lilien M, Van De Kar N, Woff E, Heymans H (2002) Increased arterial stiffness in young adults with end-stage renal disease since childhood. J Am Soc Nephrol 13:2953–2961

    Article  PubMed  Google Scholar 

  52. Mitsnefes MM, Daniels SR, Scwartz SM, Meyer RA, Khoury P, Strife CF (2000) Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 14:898–902

    Article  PubMed  Google Scholar 

  53. Nayir A, Bilge I, Kilicaslan I, Ander H, Emre S, Sirin A (2001) Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant 16:2041–2047

    Article  PubMed  Google Scholar 

  54. Goodman W, Goldin J, Kuizon B, Chun Y, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff R, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng J Med 342:1478–1483

    Article  Google Scholar 

  55. Silverstein D, Palmer J, Polinsky M, Braas C, Conley S, Baluarte H (2000) Risk factors for hyperlipidemia in long-term pediatric transplant recipients. Pediatr Nephrol 14:105–110

    Article  PubMed  Google Scholar 

  56. Jacobson SH, Egverg N, Hylander B, Lundahl J (2002) Correlation between soluble markers of endothelial dysfunction in patients with chronic renal failure. Am J Nephrol 22:42–47

    Article  PubMed  Google Scholar 

  57. Zoccali C, Benedetto FA, Mallamaci F, Tripipi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Nicocia G, Buemi M (2003) Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest 33:561–566

    Article  PubMed  Google Scholar 

  58. Turi S, Friedman A, Bereczki C, Papp F, Kovacs J, Karg E, Nemeth I (2003) Oxidative stress in juvenile essential hypertension. J Hypertens 21:145–152

    Article  PubMed  Google Scholar 

  59. Aggoun Y, Niaudet P, Laffont A, Sidi D, Kachaner J, Bonnet D (2000) Cardiovascular impact of end-stage renal insufficiency. Arch Mal Coeur Vaiss 93:1009–1013

    PubMed  Google Scholar 

  60. Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2003) Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation 107:864–868

    Article  PubMed  Google Scholar 

  61. Ma KK, Ogawa T, de Bold AJ (2004) Selective upregulation of cardiac brain natriuretic peptide at the transcriptional levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 36:505–513

    Article  PubMed  Google Scholar 

  62. Nishimura M, Hashimoto T, Kobayashi H, et al (2003) Possible involvement of TNF-alpha in left ventricular remodeling in hemodialysis patients. J Nephrol 16:641–649

    PubMed  Google Scholar 

  63. Mitsnefes MM, Kimball TR, Daniels SR (2003) Office and ambulatory blood pressure elevation in children with chronic renal failure. Pediatr Nephrol 18:145–149

    PubMed  Google Scholar 

  64. Lingens N, Dobos E, Witte K, Busch C, Lemmer B, Klaus G, Scharer K (1997) Twenty-four-hour ambulatory blood pressure profiles in pediatric patients after renal transplantation. Pediatr Nephrol 11:23–26

    Article  PubMed  Google Scholar 

  65. Node K, Fujit M, Kitakaze M, Hori M, Liao JK (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108:839–843

    Article  PubMed  Google Scholar 

  66. Sanjad S, Al-Abbad A, Al-Shorafa S (1997) Management of hyperlipidemia in children with refractory nephritic syndrome: the effect of statin therapy. J Pediatr 130:470–474

    PubMed  Google Scholar 

  67. Argent E, Kainer G, Aitken M, Rosenberg AR, Mackie F (2003) Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant 7:38–42

    Article  PubMed  Google Scholar 

  68. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GYH (2004) Endothelial dysfunction and damage in congestive heart failure. Relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage and brain natriuretic peptide. Circulation 110:1794–1798

    Article  PubMed  Google Scholar 

  69. Cheng V, Kazanagra R, Garcia A, et al (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37:386–391

    Article  PubMed  Google Scholar 

  70. Yokota N, Yamamoto Y, Aburaya N, Kitamura K, Eto T, Kangawa K, et al (1991) Increased secretion of brain natriuretic peptide and atrial natriuretic peptide, but not sufficient to induce natriuresis in rats with nephrotic syndrome. Biochem Biophys Res Commun 174:128–135

    Article  PubMed  Google Scholar 

  71. Mallamaci F, Zoccali C, Tripeti, et al (2001) Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59:1559–1566

    Article  PubMed  Google Scholar 

  72. Zoccali C, Mallamaci F, Benedetto, et al (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12:1508–1515

    PubMed  Google Scholar 

Download references

Acknowledgments

This study has been funded, in part, by an official post-doctorate grant sponsored by The Government of Spain (Ministerio de Educacion y Ciencia. Beca Post-Doctoral, ref EX2004–0350) and by an “Excellence in Academic Medicine Grant” from The Illinois Department of Public Aid.

Author information

Authors and Affiliations

  1. Division of Kidney Diseases, Children’s Memorial Hospital, 2300 Children’s Plaza 37, Chicago, IL 60614, USA

    Gema Ariceta

  2. Division of Pediatric Kidney Diseases and Children’s Memorial Hospital, Feinberg Medical School, Northwestern University, Chicago, Illinois, USA

    Gema Ariceta, Ellen R. Brooks & Craig B. Langman

Authors
  1. Gema Ariceta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen R. Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Craig B. Langman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gema Ariceta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ariceta, G., Brooks, E.R. & Langman, C.B. Assessing cardiovascular risk in children with chronic kidney disease. B-type natriuretic peptide: a potential new marker. Pediatr Nephrol 20, 1701–1707 (2005). https://doi.org/10.1007/s00467-005-1954-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-005-1954-1

Keywords

Search

Navigation